mRNA

Events

Partner Content

LNP Formulation and Process Development in Pharma | April 12...

Embrace Technology Innovations to Optimise LNP Formulation, Alternative LNP Raw Materials, Process Control to Achieve Seamless Scale-Up, Compliance & Cos

News

scientifically visualization of a coronavirus spike protein

Pfizer, Moderna are prepping new vaccines for Omicron

With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of

R&D

Beyond the pandemic: the potential of mRNA technology

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease.

News

Another mRNA company gets snapped up as Merck buys Exelead

The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead.

News

Look out GSK, Pfizer and BioNTech are coming for Shingrix

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion.

News

Chinese tech giant Baidu licenses mRNA algorithm to Sanofi

Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company.

LNP Formulation and Process Development in Pharma | April 12...

Pfizer, Moderna are prepping new vaccines for Omicron

Beyond the pandemic: the potential of mRNA technology

Another mRNA company gets snapped up as Merck buys Exelead

Look out GSK, Pfizer and BioNTech are coming for Shingrix

Chinese tech giant Baidu licenses mRNA algorithm to Sanofi

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

mRNA

Editor's Picks